These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 19229536)

  • 21. Acute and repeat-dose toxicity studies of the (6-maleimidocaproyl)hydrazone derivative of doxorubicin (DOXO-EMCH), an albumin-binding prodrug of the anticancer agent doxorubicin.
    Kratz F; Ehling G; Kauffmann HM; Unger C
    Hum Exp Toxicol; 2007 Jan; 26(1):19-35. PubMed ID: 17334177
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Folate-targeted enzyme prodrug cancer therapy utilizing penicillin-V amidase and a doxorubicin prodrug.
    Lu JY; Lowe DA; Kennedy MD; Low PS
    J Drug Target; 1999; 7(1):43-53. PubMed ID: 10614814
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Synthesis and antitumor efficacy of a β-glucuronidase-responsive albumin-binding prodrug of doxorubicin.
    Legigan T; Clarhaut J; Renoux B; Tranoy-Opalinski I; Monvoisin A; Berjeaud JM; Guilhot F; Papot S
    J Med Chem; 2012 May; 55(9):4516-20. PubMed ID: 22515366
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2.
    Mansour AM; Drevs J; Esser N; Hamada FM; Badary OA; Unger C; Fichtner I; Kratz F
    Cancer Res; 2003 Jul; 63(14):4062-6. PubMed ID: 12874007
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Design of a paclitaxel prodrug conjugate for active targeting of an enzyme upregulated in breast cancer cells.
    Satsangi A; Roy SS; Satsangi RK; Vadlamudi RK; Ong JL
    Mol Pharm; 2014 Jun; 11(6):1906-18. PubMed ID: 24847940
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Synthesis and biological activity of water-soluble maleimide derivatives of the anticancer drug carboplatin designed as albumin-binding prodrugs.
    Warnecke A; Fichtner I; Garmann D; Jaehde U; Kratz F
    Bioconjug Chem; 2004; 15(6):1349-59. PubMed ID: 15546202
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Extracellularly tumor-activated prodrugs for the selective chemotherapy of cancer: application to doxorubicin and preliminary in vitro and in vivo studies.
    Trouet A; Passioukov A; Van derpoorten K; Fernandez AM; Abarca-Quinones J; Baurain R; Lobl TJ; Oliyai C; Shochat D; Dubois V
    Cancer Res; 2001 Apr; 61(7):2843-6. PubMed ID: 11306455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Linkage with cathepsin B-sensitive dipeptide promotes the in vitro and in vivo anticancer activity of PEGylated tumor necrosis factor-alpha (TNF-α) against murine fibrosarcoma.
    Dai C; Fu Y; Li B; Wang Y; Zhang X; Wang J; Zhang Q
    Sci China Life Sci; 2011 Feb; 54(2):128-38. PubMed ID: 21318482
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of enzymatically cleavable prodrugs derived from dendritic polyglycerol.
    Calderón M; Graeser R; Kratz F; Haag R
    Bioorg Med Chem Lett; 2009 Jul; 19(14):3725-8. PubMed ID: 19553109
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Synthesis, Characterization and in vitro Studies of a Cathepsin B-Cleavable Prodrug of the VEGFR Inhibitor Sunitinib.
    Karnthaler-Benbakka C; Koblmüller B; Mathuber M; Holste K; Berger W; Heffeter P; Kowol CR; Keppler BK
    Chem Biodivers; 2019 Jan; 16(1):e1800520. PubMed ID: 30566287
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development of albumin-binding camptothecin prodrugs using a Peptide positional scanning library.
    Schmid B; Warnecke A; Fichtner I; Jung M; Kratz F
    Bioconjug Chem; 2007; 18(6):1786-99. PubMed ID: 17915955
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cathepsin B-sensitive dipeptide prodrugs. 1. A model study of structural requirements for efficient release of doxorubicin.
    Dubowchik GM; Firestone RA
    Bioorg Med Chem Lett; 1998 Dec; 8(23):3341-6. PubMed ID: 9873731
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors.
    Pan C; Cardarelli PM; Nieder MH; Pickford LB; Gangwar S; King DJ; Yarranton GT; Buckman D; Roscoe W; Zhou F; Salles A; Chen TH; Horgan K; Wang YH; Nguyen T; Bebbington CR
    Cancer Res; 2003 Sep; 63(17):5526-31. PubMed ID: 14500390
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Optimization of an albumin-binding prodrug of Doxorubicin that is cleaved by prostate-specific antigen.
    Elsadek B; Graeser R; Warnecke A; Unger C; Saleem T; El-Melegy N; Madkor H; Kratz F
    ACS Med Chem Lett; 2010 Aug; 1(5):234-8. PubMed ID: 24900200
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of combination therapy schedules of doxorubicin and an acid-sensitive albumin-binding prodrug of doxorubicin in the MIA PaCa-2 pancreatic xenograft model.
    Kratz F; Azab S; Zeisig R; Fichtner I; Warnecke A
    Int J Pharm; 2013 Jan; 441(1-2):499-506. PubMed ID: 23149257
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Acid-activatable prodrug nanogels for efficient intracellular doxorubicin release.
    Zhan F; Chen W; Wang Z; Lu W; Cheng R; Deng C; Meng F; Liu H; Zhong Z
    Biomacromolecules; 2011 Oct; 12(10):3612-20. PubMed ID: 21905663
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cytosine arabinoside prodrug designed to bind plasma serum albumin for drug delivery.
    Wei W; He Z; Yang J; Sun M; Sun J
    Drug Deliv Transl Res; 2018 Oct; 8(5):1162-1170. PubMed ID: 29748833
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CPI-0004Na, a new extracellularly tumor-activated prodrug of doxorubicin: in vivo toxicity, activity, and tissue distribution confirm tumor cell selectivity.
    Dubois V; Dasnois L; Lebtahi K; Collot F; Heylen N; Havaux N; Fernandez AM; Lobl TJ; Oliyai C; Nieder M; Shochat D; Yarranton GT; Trouet A
    Cancer Res; 2002 Apr; 62(8):2327-31. PubMed ID: 11956091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. PSA-specific and non-PSA-specific conversion of a PSA-targeted peptide conjugate of doxorubicin to its active metabolites.
    Wong BK; DeFeo-Jones D; Jones RE; Garsky VM; Feng DM; Oliff A; Chiba M; Ellis JD; Lin JH
    Drug Metab Dispos; 2001 Mar; 29(3):313-8. PubMed ID: 11181501
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PDEPT: polymer-directed enzyme prodrug therapy. 2. HPMA copolymer-beta-lactamase and HPMA copolymer-C-Dox as a model combination.
    Satchi-Fainaro R; Hailu H; Davies JW; Summerford C; Duncan R
    Bioconjug Chem; 2003; 14(4):797-804. PubMed ID: 12862433
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.